What is the medical treatment for Substance Use Disorder (SUD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medical Treatment for Substance Use Disorder (SUD)

The most effective treatment for substance use disorder (SUD) involves an integrated approach combining pharmacotherapy with evidence-based behavioral therapies, tailored to the specific substance used and individual needs. 1

Comprehensive Treatment Approach

Assessment and Screening

  • All individuals at risk for or with HIV should receive screening, diagnosis, and treatment for SUDs 1
  • Early identification of substance use problems is critical, using standardized screening tools in healthcare settings 1
  • Screening, Brief Intervention, and Referral to Treatment (SBIRT) should be implemented in various settings including primary care 1

Pharmacotherapy Options

  • FDA-approved medications are available for specific SUDs: 1
    • Opioid use disorder: methadone, buprenorphine, naltrexone, and buprenorphine/naloxone combinations 1, 2
    • Alcohol use disorder: naltrexone and acamprosate 1
    • Tobacco use disorder: nicotine replacement therapy, bupropion, and varenicline 1
    • No FDA-approved medications currently exist for cocaine, stimulant, or cannabis use disorders 1, 3

Behavioral Therapies

  • Evidence-based behavioral approaches should be provided for all SUDs, including: 1
    • Cognitive-behavioral therapy (CBT)
    • Contingency management
    • Motivational enhancement therapy
    • Relapse prevention strategies 1
  • Combined pharmacotherapy with CBT shows greater efficacy than usual care with pharmacotherapy 1
  • CBT performs similarly to other evidence-based therapies when combined with pharmacotherapy 1

Substance-Specific Approaches

Opioid Use Disorder

  • Medication-assisted treatment (MAT) is the gold standard, combining medications with behavioral therapies 1
  • Methadone must be provided through certified Opioid Treatment Programs (OTPs) 2
  • Buprenorphine can be prescribed in office-based settings by qualified providers 1
  • Naloxone should be provided for overdose prevention as part of harm reduction 1

Alcohol Use Disorder

  • First-line pharmacotherapy includes naltrexone and acamprosate 1
  • Medication treatment of alcohol use disorder improves antiretroviral therapy adherence and viral suppression in people with HIV 1

Stimulant Use Disorders

  • Primarily treated with behavioral therapies as no FDA-approved medications exist 1
  • Contingency management shows the strongest evidence for effectiveness 1
  • Clinical guidelines recommend pharmacotherapies in certain situations despite lack of FDA approval 1

Special Considerations

Co-occurring Mental Health Disorders

  • Integrated treatment for co-occurring mental health disorders and SUDs is essential 1, 4
  • Clozapine shows efficacy for individuals with schizophrenia and SUD 4
  • Naltrexone is effective for individuals with severe mental illness and comorbid alcohol use disorders 4

Harm Reduction

  • Harm reduction services should be offered to all persons who report drug use, including: 1
    • Naloxone distribution
    • Safe injection education
    • Fentanyl and xylazine drug test strips
    • Referral to syringe service programs 1

Treatment Delivery Considerations

  • SUD treatment should be integrated into HIV prevention and treatment services 1
  • Peer support, telehealth, extended hours, mobile clinics, and walk-in options improve accessibility 1
  • Treatment should follow a chronic care model with intensity adjusted to disorder severity 5

Emerging Approaches

  • Neuromodulation techniques (transcranial magnetic stimulation) show promise as adjunctive treatments 1
  • Novel pharmacological targets being investigated include serotonin 2A receptors, glucagon-like peptide 1 receptors, and the orexin/hypocretin system 3
  • Digital interventions for prevention, early intervention, and treatment are expanding access options 1

Common Pitfalls to Avoid

  • Withholding SUD medications due to concerns about drug interactions with HIV or HCV treatments (most have few clinically significant interactions) 1
  • Focusing solely on abstinence rather than harm reduction approaches 1
  • Failing to address stigma, which remains a significant barrier to treatment access 5
  • Neglecting continuing care services, which are essential for long-term recovery 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.